WPWM
CRVS icon

Western Pacific Wealth Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Western Pacific Wealth Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.3K Hold
2,000
– – 0.03% 139
2025
Q4 		$15.4K Hold
2,000
– – 0.01% 135
2025
Q3 		$14.7K Hold
2,000
– – 0.01% 154
2025
Q2 		$8K Hold
2,000
– – 0.01% 168
2025
Q1 		$6.36K Hold
2,000
– – 0.01% 169
2024
Q4 		$10.7K Hold
2,000
– – 0.01% 167
2024
Q3 		$10.6K Buy
+2,000
New +$7.18K 0.01% 205

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Western Pacific Wealth Management's CRVS Position: Q1 2026 in Review

Western Pacific Wealth Management held its Corvus Pharmaceuticals (CRVS) position steady in Q1 2026 at 2,000 shares worth $29.3K. The position accounts for 0.03% of the portfolio, ranked #139.

Western Pacific Wealth Management first reported a position in CRVS in Q3 2024 and has held it in 7 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Western Pacific Wealth Management held 2,000 shares of Corvus Pharmaceuticals worth $29.3K as of Q1 2026.
  • Western Pacific Wealth Management left its Corvus Pharmaceuticals share count unchanged in Q1 2026.
  • Corvus Pharmaceuticals made up 0.03% of Western Pacific Wealth Management's portfolio in Q1 2026, its #139 holding.
  • Western Pacific Wealth Management first reported a position in Corvus Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Western Pacific Wealth Management's 13F filing for Q1 2026, filed 17 Apr 2026.